Coronary angiography holds a central role in the diagnosis of coronary heart disease. We studied temporal trends in referral patterns 2000-09.
Introduction
Coronary heart disease has a profound effect on health worldwide. At age 40, the associated lifetime risk of developing coronary heart disease is 48.6% among men and 31.7% among women. 1 Despite advances in the field of non-invasive coronary artery testing and imaging, invasive coronary angiography (CAG) remains the 'golden standard' for diagnosing coronary heart disease. 2 Although being a rather cheap and safe procedure, coronary artery rupture, provocation of cardiac dysrhythmias, and arterial pseudoaneurisms are among the most severe complications. Selection of appropriate patients for referral is therefore paramount in order to avoid under and over utilization. Previous studies have primarily been focusing on acute CAG procedures, 3 -5 where time until invasive procedure and risk of subsequent events has been of great interest in the referral of appropriate acute patients for CAG. However, in patients referred for elective CAG, other factors such as prophylactic pharmacotherapy including RAS-inhibitors, statins, and antithrombotic treatment as well as the individual burden of comorbidities, might be more prominent determinants for the risk of future adverse events. The aim of this paper is to describe changes in population characteristics and use of prophylactic cardiovascular drugs in a nationwide cohort of patients referred for CAG in Denmark between 2000 and 2009.
Methods

Study design
This study was a nationwide cohort study including patients undergoing CAG in Denmark. The study period began 1 January 2000 and ended 31 December 2009. All Danish citizens are given a unique and permanent identification number at birth or first date of immigration. By use of this number, we were able to link nationwide administrative registers on an individual level. 6 
Study population and data sources
To identify our study population, we used the nationwide Danish Heart Register. 7 Information on invasive cardiac procedures, i.e. CAG, percutaneous coronary intervention, coronary artery by-pass graft, and valve surgery has been reported to the Danish Heart Registry since 2000 by all invasive clinics in Denmark performing these procedures. We identified all patients who were referred to CAG between 2000 and 2009. Only first-time procedures within this period were included. The population was, for descriptive purposes, divided into four groups i.e. acute patients with previously diagnosed ischaemic heart disease (acute with prior IHD), elective patients with previously diagnosed IHD (elective with prior IHD), acute patients without previously diagnosed IHD (acute no prior IHD), and elective patients without previously diagnosed IHD (elective no prior IHD). Moreover, subpopulations with a previously diagnosed chronic condition of IHD, peripheral vascular disease, cerebrovascular disease, diabetes, or chronic heart failure were investigated separately with respect to trends in pharmacological treatment patterns. A history of pharmacotherapy for the individual patient was retrieved from the Danish Register of Medicinal Product Statistics (national prescription register). The register holds information on all prescribed drugs dispensed since 1995 including strength, date of dispensing, and quantity. All drugs are coded according to the international Anatomical Therapeutic Chemical (ATC) classification system. Due to partial reimbursement of drug expenses by healthcare authorities, all pharmacies in Denmark are required to register dispensed drug prescriptions in the registry, which ensures complete registration. 8 Information on comorbidities, diagnosed at any time prior to the procedure, was obtained from the Danish National Patient Registry, which holds information on all hospital treatments nationwide since 1978. At discharge, each admission is registered according to the International Classification of Diseases 10th revision (ICD-10) since 1994.
Comorbidities
Comorbidities, i.e. IHD, cerebrovascular disease, arrhythmias, chronic obstructive pulmonary disease, liver disease, renal disease, peripheral vascular disease, and acute myocardial infarction were defined solely from ICD codes. Chronic heart failure patients were identified from either a diagnosis of chronic heart failure or from the use of loop diuretics, as done previously. 9 Similarly, patients with diabetes were identified by the diabetes diagnosis or by a prescription for glucose lowering agents. 10 Comorbidities were included if present more than 30 days prior to the CAG, in order not to include diagnoses given to the patient when presenting for CAG. A Charlson score was calculated as an indicator of the cumulative burden of comorbidities; acute myocardial infarction was not included (because it was likely the indication for CAG in some patients). 11 ICD coding for all comorbidities is available in Supplementary material online, 
Ethics
Ethical approval as well as informed consent is not warranted for register studies in Denmark. The authors had full access to raw data provided by Statistics Denmark (complete anonymity was ensured through encrypted personal identification numbers). This study was approved by the Danish protection agency, approval number 2007-58-0014.
Results
A total of 156 496 first-time CAG procedures were identified. Patient characteristics, use of pharmacotherapy, and history of comorbidities are shown for 2-year intervals in Table 1 . Table 1 and Table S2 ). Increased odds ratios for treatment with acetylsalicylic acid, RAS-inhibitors, and statins were observed for later years, compared with 2000-01, whereas treatment with beta-blockers declined during the study period ( Figure 1 ). Odds ratios for other drugs are presented in Supplementary material online, Table S3 . At the time of CAG, elective patients were more frequently treated with cardiovascular drugs compared with acute patients ( Figure 2 ).
Subgroups
The main CAG population was divided into four subgroups. Characteristics for all groups by 2-year intervals are presented in Supplementary material online, Table S4 . Total numbers of procedures performed more than doubled between 2000-01 and 2008-09 in the group 'acute no prior IHD patients' (4062-8956) and 'elective no prior IHD patients' (7826-17575), whereas the number of procedures per year in the two remaining groups were more or less constant ( Figure 3) . As for the combined population, mean age and the female proportion of patients increased in all subgroups except 'acute no prior IHD patients' where a small decrease in the proportion of females was observed. The proportion of patients subjected to CAG procedure the same day as hospitalized increased in 'acute no prior IHD patients' (59.9 vs. 84.0%) and 'acute with prior IHD patients' (49.4 vs. 78.6%), between 2000-01 and 2008-09. With respect to drug treatment, the four groups largely followed the trends described for the combined population discussed earlier.
The burden of comorbidities was overall markedly higher for patients with prior IHD compared with no prior IHD patients. During our 10-year period, we observed a marked decrease in the proportion of patients with prior acute myocardial infarction for all subgroups. Temporal trends in coronary angiography 
Atherosclerotic diseases
The use of RAS-inhibitors, acetylsalicylic acid, and statins were investigated separately in patients with a history of atherosclerotic diseases, i.e. IHD, cerebrovascular disease, peripheral vascular disease, or diabetes ( Table 2 ). The use of statins increased in all groups during the study period, with a marked increase between 2002-03 and 2004-05. Treatment with acetylsalicylic acid was found to increase 4.2 -9.0 percentage points in the four groups, along with an increase of 12.6-17.5 percentage points in use of RAS-inhibitors. Dividing the subpopulations by gender, age groups, and acute/ elective patients revealed no gender differences for drug treatment (data not shown). Older age was associated with higher frequency of drug use, except for the group of 80+, in which statin treatment was low. Elective patients were more intensively treated than acute patients regarding all three medications.
Heart failure
Treatment with RAS-inhibitors, aldosterone antagonists, and betablockers increased among patients with previously diagnosed chronic heart failure during the study period. Stratifying by gender, age groups, and elective/acute patients (data not shown), showed that men were more frequently treated than women and elective patients more frequently treated than acute patients. No marked differences were found for different age groups. 
Discussion
Coronary angiographies per year
Overall, we observed an increase in the numbers of CAG procedures performed annually. Analyses of our subgroups, i.e. acute and elective patients with and without previously diagnosed IHD, revealed that the increase in number of procedures per year was due to the two groups of patients with no prior IHD which more than doubled in numbers. Interpretation of these findings may, however, be complicated by the fact that the annual incidence of acute myocardial infarctions in Denmark has decreased during our 10-year period and the introduction of troponin as the main diagnostic biomarker. 12, 13 Several major studies suggesting a beneficial effect of CAG followed by invasive strategies was performed at the beginning of our study period. The Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC-2) study from 1999 included hospitalized patients with unstable coronary artery disease and myocardial ischaemia verified by ECG or biomarkers, and concluded that an early invasive strategy were superior to a conservative approach.
14 Later on, The Danish Trial in Acute Myocardial Infarction (DANAMI-2) was performed. The trial faced a premature termination in 2003 when interim analysis revealed invasive therapy to be superior to fibrinolysis in patients with ST-elevated myocardial infarction. 15 These studies may have contributed to the 92% increase in acute CAG procedures observed from 2000-01 to 2006-07. In accordance with the established importance of a rapid invasive approach, we found that the proportion of acute patients treated the same day as admitted to the hospital increased from around 50 -60% in 2000-01 to 80% in 2008-09. Additional capacity in Figure 3 Trends in number of procedures per 2-year interval stratified by urgency and prevalent ischaemic heart disease. The number of procedures in 'acute no prior IHD patients' and 'elective no prior IHD patients' more than doubles during our 10-year study period.
Temporal trends in coronary angiography CAG labs to cope with increasing demands for acute procedures may also have contributed to an increased number of elective procedures during daytime. In the later years of the study period, the numbers of procedures were seen to level. Around this time, results from randomized clinical trials and meta-analyses were published, indicating that invasive treatment in patients with stable coronary artery disease was only beneficial for symptom relief, but not for long-term outcome (e.g. death, acute myocardial infarction, and subsequent revascularization). 16 -18 The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) study, published in 2007, challenged the increasing role of percutaneous coronary intervention as the initial treatment in patients with stable coronary artery disease, and might have contributed to a late decrease in the annual number of CAGs. 19 While introduction of Coronary angiography-CT 20 might be thought of as the reason for the decline in number of conventional CAGs per year, these procedures were not implemented in the Danish healthcare system until 2010. proportion increased slightly. Studies including women with unstable angina pectoris showed that CAG in women were associated with increased likelihood of revealing no significant stenoses and a speculated poorer long-term outcome in females after revascularization, compared with male patients. 21 -24 Further studies focusing on the indication for CAG are warranted to investigate the gender-specific changes in more detail.
Trends in gender distribution
Pharmacotherapy
Around the year 2000, RAS-inhibitors and statins were confirmed to be very effective in protection from cardiovascular disease and atherosclerosis, even beyond the benefit attributable to their primary target effect. 25 -28 The Heart Outcomes Prevention Evaluation (HOPE) study from 2000 found that RAS-inhibitors were beneficial in the prevention of stroke and acute myocardial infarction in high-risk patients. 29 Also, as demonstrated in the Heart Protection Study (HPS) from 2004, lipid-lowering therapy with 40 mg of statins was indicated for prevention of cardiac events, independent of baseline cholesterol level. 30 The increased focus correlates well with increased use of statins and RAS-inhibitors in our population, and especially the marked increase in use of statins observed between 2002-03 and 2004-05, which in addition points towards a rapid incorporation of new knowledge in the Danish healthcare system. Elective patients were found to be more frequently treated with relevant prophylactic pharmacotherapy, compared with acute patients. Different referral patterns are thought to be part of the explanation. Elective patients are usually referred by their general practitioner a couple of weeks ahead of the procedure, but immediately started in pharmacological prophylactic treatment in case of suspect coronary artery disease. In this way, elective patients will be more intensely treated than acute patients, when presenting for CAG. Another explanation is that more intense prophylactic treatment of the elective patients is the underlying reason for them ending up with an elective procedure (e.g. due to heart failure, atrial fibrillation with abnormal left-ventricular wall motions etc.), whereas the lesstreated patients are more likely to encounter an acute procedure. These hypotheses remain to be further investigated.
Treatment of chronic diseases
Subpopulations were analyzed in order to assess the level of secondary prevention treatment in groups of patients with a history of diagnosed chronic diseases, i.e. IHD, peripheral vascular disease, cerebrovascular disease, diabetes, or chronic heart failure. Exploring guidelines for secondary treatment, it is evident that acetylsalicylic acid and statins are indicated for all patients with a history of IHD, peripheral vascular disease, cerebrovascular disease, and diabetes, with only few exceptions. 31 -34 Also, in 2004, two expert consensus papers were published by the European Society of Cardiology. One favoured the use of RAS-inhibitors for general vascular protection in patients with heart failure, acute myocardial infarction, hypertension, cardiovascular disease, or diabetes, and one other risk factor. 35 The other favoured prophylactic use of acetylsalicylic acid in various conditions such as ischaemic heart disease, prior acute myocardial infarction, prior stroke, and peripheral vascular disease. 36 The treatment prevalence for acetylsalicylic acid and statins in known atherosclerotic patients varied from 62 to 70% and 65 to 73%, respectively in 2008-09, which were lower than recommended in guidelines.
Regarding the chronic heart failure subpopulation, RAS-inhibitors and beta-blockers are indicated for all patients with systolic heart failure. 37 The treatment level of RAS-inhibitors and beta-blockers in 2008-09 were 61 and 52%, respectively, among heart failure patients. However, no conclusions on whether these patients were adequately managed can be drawn because of lack of data on, e.g. leftventricular ejection fraction. When summarizing our findings in brief, we notice that the Danish healthcare system has undergone rapid adjustments and implementation of new knowledge regarding IHD and utilization of the CAG procedures. Moreover, the CAG procedure has become a wellintegrated diagnostic tool, with an overall increase in patients with a large burden of comorbidities and previously 'healthy' patients, referred for invasive testing. In addition, the group of elderly patients constitutes a growing proportion of the Danish population, and has as such increased in total numbers. Whether the increased use of invasive testing will translate into improved disease control, improved treatments, and lower mortality remains to be answered and, if possible, compared with non-invasive strategies that might be more cost-effective. Future studies should aim to address these key questions as more comprehensive longitudinal data becomes available.
Strengths and limitations
Lack of information on indication for CAG investigation is an important limitation of this study. In order to identify subpopulations, we used diagnosis from registers combined with data on claimed prescriptions. This method is thought to be acceptable for the purpose of this study, but we cannot rule out that some patients may have been misclassified. Furthermore, clinical data such as echocardiographic variables, blood samples, and physical fitness (e.g. anginascore and NYHA class) were lacking for the present study, which could have helped in characterizing patients even better. The Danish healthcare system is tax funded and equally available to all Danish citizens eliminating treatment differences between social classes. Hence, our results cannot be extrapolated directly to other societies where this is not the case.
In conclusion, the total number of CAGs carried out in Denmark per year was found to increase between 2000 and 2009. This increase was mainly due to an increased number of patients with no prior diagnosed ischaemic heart disease. The increase was seen for elective as well as acute procedures and acute patients were more often subjected to CAG at the same day as submitted to the hospital. The mean age of the patients, the proportion of female patients, and prophylactic treatment of patients with statins, acetylsalicylic acid, and RAS-inhibitors increased during our study period in accordance with evolving scientific evidence and guidelines. These findings point towards an increased capacity and willingness in the Danish healthcare system to subject a larger variety of patients to coronary angiography. 
